No S-ICU-DD | S-ICU-DD | p | |||
---|---|---|---|---|---|
No weakness | ICU-AW | No weakness | ICU-AW | ||
N | 36 (31%) | 32 (28%) | 14 (12%) | 34 (29%) | |
Demographic data | |||||
Men, n (%) | 27 (75) | 19 (59) | 7 (58) | 24 (71) | 0.522 |
Age, years | 58 (40–55) | 56 (50–65) | 70 (50–78)* | 64 (56–75)*# | 0.009 |
Body mass index, kg/m2 | 24 (21–27) | 23 (21–26) | 24 (20–33) | 25 (22–29) | 0.302 |
Medical conditions | |||||
COPD, n (%) | 7 (19) | 0 (0)* | 3 (21)# | 7 (21) # | 0.049 |
Heart failure, n (%) | 7 (19) | 2 (6) | 2 (14) | 6 (18) | 0.453 |
Reason for ICU admission | |||||
Shock | 11 (33) | 10 (31) | 3 (21) | 13 (38) | 0.793 |
Coma | 13 (39) | 5 (19) | 3 (21) | 6 (18) | 0.186 |
Acute respiratory failure | 12 (33) | 17 (53) | 8 (57) | 15 (44) | 0.387 |
On admission | |||||
SOFA | 4 (3–5) | 7 (4–10)* | 6 (5–8)* | 8 (5–13)* | < 0.0001 |
Sepsis, n (%) | 24 (67) | 23 (72) | 7 (58) | 23 (68) | 0.830 |
At inclusion | |||||
MV prior to inclusion, days | 3 (1–5) | 4 (4–9) | 5 (1–7)* | 9 (5–15)*† | < 0.0001 |
Medication exposure | |||||
Neuromuscular blocker, n (%) | 4 (11) | 13 (41)* | 4 (28) | 17 (50)* | 0.017 |
Corticosteroids, n (%) | 1 (3) | 3 (9) | 4 (28)* | 1 (3)† | < 0.0001 |
Norepinephrine, n (%) | 9 (25) | 21 (66)* | 3 (21)# | 30 (88)*† | < 0.0001 |
Midazolam, n (%) | 11 (31) | 16 (50) | 5 (36) | 13 (38) | 0.346 |
Propofol (%) | 23 (64) | 5 (19)* | 7 (50)# | 5 (15)*† | < 0.0001 |
Sufentanil, n (%) | 16 (44) | 21 (66) | 7 (50) | 31 (91)* †# | 0.001 |
Muscle assessment | |||||
Ptr,stim, cmH2O | 10.9 (7.9–15.3) | 11.0 (9.0–14.0) | 5.0 (4.1–6.3)*# | 3.5 (2.4–6.3)*# | < 0.0001 |
MRC score | 56 (51–59) | 35 (23–43)* | 55 (51–57)# | 33 (24–40)*† | < 0.0001 |